Premium
MLL ‐rearranged acute myeloid leukemia: Influence of the genetic partner in allo‐ HSCT response and prognostic factor of MLL 3′ region mRNA expression
Author(s) -
BurilloSanz Sergio,
MoralesCamacho Rosario M.,
CaballeroVelázquez Teresa,
Carrillo Estrella,
Sánchez Javier,
PérezLópez Olga,
Pérez de Soto Inmaculada,
González Campos José,
PratsMartín Concepción,
Bernal Ricardo,
Vargas María Teresa
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13037
Subject(s) - myeloid leukemia , leukemia , medicine , fusion gene , gene , oncology , context (archaeology) , cohort , cancer research , immunology , biology , genetics , paleontology
Abstract Objective MLL gene is involved in more than 80 known genetic fusions in acute leukemia. To study the relevance of MLL partner gene and selected gene's expression, in this work, we have studied a cohort of 20 MLL ‐rearranged acute myeloid leukemia ( AML ). Methods Twenty MLL ‐rearranged AML patients along with a control cohort of 138 AML patients are included in this work. By RT ‐ PCR and sequencing, MLL genetic fusion was characterized, and relative gene expression quantification was carried out for EVI 1 , MEIS 1 , MLL ‐3′, RUNX 1 , SETBP 1 , HOXA 5, and FLT 3 genes. Risk stratification and association of MLL genetic partner and gene expression to overall survival, in the context of received therapy, were performed. Results MLL r cohort showed to have an OS more similar to intermediate‐risk AML . Type of MLL genetic partner showed to be relevant in allo‐ HSCT response; having MLLT 1 and MLLT 3, a better benefit from it. Expression of MLL ‐3′ region, EVI 1 and FLT 3 , showed association with OS in patients undergoing allo‐ HSCT . Conclusion We show that the MLL genetic partner could have implications in allo‐ HSCT response, and we propose three genes whose expression could be useful for the prognosis of this leukemia in patients undergoing allo‐ HSCT : 3′ region of MLL , EVI 1, and FLT 3 .